Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ ICU admission 88% Improvement Relative Risk c19hcq.org Dubernet et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 36 patients in France Lower ICU admission with HCQ (p=0.008) Dubernet et al., J. Global Antimicrobial Resista.., doi:10.1016/j.jgar.2020.08.001 Favors HCQ Favors control
A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: results of a retrospective observational study in the French overseas department of Reunion Island
Dubernet et al., J. Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.08.001
Dubernet et al., A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or.., J. Global Antimicrobial Resistance, doi:10.1016/j.jgar.2020.08.001
Aug 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective analysis of 36 hospitalized patients showing HCQ/AZ associated with lower ICU admission, p=0.008. Median age 66, no mortality. Confounding by indication, however it was patients with hypoxemic pneumonia that were treated with HCQ/AZ, patients were not treated with HCQ/AZ if they didn't need oxygen therapy.
risk of ICU admission, 87.6% lower, RR 0.12, p = 0.008, treatment 1 of 17 (5.9%), control 9 of 19 (47.4%), NNT 2.4.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Dubernet et al., 20 Aug 2020, retrospective, France, peer-reviewed, median age 66.0, 20 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Journal of Global Antimicrobial Resistance 23 (2020) 1–3 Contents lists available at ScienceDirect Journal of Global Antimicrobial Resistance journal homepage: www.elsevier.com/locate/jgar Short Communication A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island Arthur Duberneta , Kevin Larsena , Laurie Massea , Jérôme Allynb,c , Emilie Focha , Lea Bruneaud,e, Adrien Maillote, Marie Lagrange-Xelotf , Vincent Thomasg , Marie-Christine Jaffar-Bandjeeg , Loraine Gauzereh , Loic Raffrayh , Karine Borsui , Servane Dibernardoi , Stéphane Renaudj , Michel Andréa , Diane Moreaua , Julien Jabotb , Nathalie Coolen-Alloua , Nicolas Alloub,c,* a Pneumologie, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France Réanimation polyvalente, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France c Département d’Informatique Clinique, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France d INSERM CIC 1410 Clinical and Epidemiology, University Hospital, Saint Pierre, Réunion Island, France e Department of Public Health and Research Support, Methodological Support and Biostatistics Unit, University Hospital, Saint Denis, Réunion Island, France f Service des Maladies Infectieuses, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France g Microbiologie, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France h Médecine Interne, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France i Médecine Polyvalente, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France j Gériatrie, Centre Hospitalier Universitaire Felix-Guyon, Allée des Topazes, 97405 Saint Denis, Réunion Island, France b A R T I C L E I N F O A B S T R A C T Article history: Received 11 June 2020 Received in revised form 22 July 2020 Accepted 1 August 2020 Available online 20 August 2020 Background: This study aimed to evaluate the prognosis of COVID-19 patients in Reunion Island, with a particular focus on the management of patients with hypoxemic pneumonia. Methods: This retrospective observational study was conducted from 11 March to 17 April 2020 at the only hospital authorized to manage patients with COVID-19 in Reunion Island. Results: Over the study period, 164 out of 398 patients (41.2%) infected with COVID-19 were admitted to Félix Guyon University Hospital. Of these, 36 (22%) developed hypoxemic pneumonia. Patients with hypoxemic pneumonia were aged 66 [56–77] years, 69% were male and 33% had hypertension. Ten patients (27.8%) were hospitalized in intensive care unit (ICU). Hydroxychloroquine/azithromycin treatment was associated with a lower ICU admission rate (P = 0.008). None of the 6 patients treated with corticosteroids were hospitalized in ICU (P = 0.16). There were no deaths at follow up (minimum 80 days). Conclusions: Despite the risk profile of COVID-19 patients with severe hypoxemic pneumonia, the mortality rate of the disease in Reunion Island was 0%. This may be due to the care bundle used in our hospital (early hospitalisation, treatment with..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit